NYSE:EVMNBiotechs
Evommune (EVMN) Valuation Check After Positive Phase 2a EVO301 Results In Atopic Dermatitis
Evommune (EVMN) is back in focus after reporting statistically significant positive top-line results from its Phase 2a EVO301 trial in moderate to severe atopic dermatitis, including clear separation from placebo and a favorable safety readout.
See our latest analysis for Evommune.
The positive EVO301 data has coincided with a sharp re-rating in the stock, with a 1-day share price return of 70.87% and a year-to-date share price return of 67.71% off a last close of $29.03. This indicates...